Watch How Your Oncotype DX Genomic Prostate Score Can Help You Navigate Your Treatment Options
Oncotype DX is the only test designed specifically for men with clinically low-risk prostate cancer. With it, you get a genomic blueprint to help you build a treatment plan that addresses your cancer AND your quality of life.
The Genomic Health Oncotype DX Prostate Cancer Assay
Prostate cancer screenings occur in 23 million men each year, with 240,000 being diagnosed with the affliction. In less severe cases, patients are quick to receive immediate treatment despite the fact that only 3% are likely to have a prostate cancer recurrence. Genomic Health provides a test for prostate cancer patients, called the Oncotype DX Prostate Cancer Test (assay), which will help determine how aggressive the prostate cancer is and aides doctors and patients in forming an individualized course of treatment.